This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
by Zacks Equity Research
INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.
INCYPositive Net Change NVSPositive Net Change LLYPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
by Sundeep Ganoria
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
JAZZPositive Net Change TLRYPositive Net Change GTBIFPositive Net Change
biotechs marijuana medical
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
by Zacks Equity Research
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
SMMTNegative Net Change MRKNegative Net Change RCUSNegative Net Change
biotechs
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
by Debanjana Dey
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
BDSXPositive Net Change BIAFPositive Net Change
biotechnology biotechs cancer medical oncology-screening
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
by Debanjana Dey
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
CSBRNegative Net Change CTKBNegative Net Change
biotechnology biotechs cancer medical oncology-screening
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
by Zacks Equity Research
BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.
BBIOPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechs medical
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
by Zacks Equity Research
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
BMYPositive Net Change SMMTNegative Net Change RVMDNegative Net Change TNGXPositive Net Change
biotechs medical
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
by Zacks Equity Research
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
RGENNegative Net Change BLFSNegative Net Change LQDANegative Net Change KNSAPositive Net Change
biotechs
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.
RDYPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
by Zacks Equity Research
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
GSKPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDANegative Net Change
biotechs